r14

R1498 is an inhibitor of cyclin-dependent kinase 2. It also acts by targeting angiogenesis and mitosis pathways. It is well-tolerated and orally active for hepatocellular carcinoma and gastric cancer treatment.

IDH2R140Q-IN-2 is an orally active and potent IDH2R140Q inhibitor with an IC50 of 29 nM.IDH2R140Q-IN-2 possesses potential antitumour activity, reducing D2HG production in TF-1 cell lines carrying the IDH2R140Q mutation (IC50 of 10 nM) and inhibiting tumour tissue D2HG levels.IDH2R140Q-IN-2 is suitable for the study of acute myeloid leukaemia (AML).

GR148672X is an inhibitor of triacyglycerol hydrolase (TGH) (IC50: 4 nM).

SR144528 is an antagonist of the CB2 receptor (Ki = 0.6 nM) and inhibits microsomal ACAT activity (IC50 = 3.6 μM).

SR14150 is a partial agonist of high-affinity NOP receptor.

SR142948A is a selective and reversible non-peptide neurotensin receptor antagonist capable of blocking hypothermia and analgesic effects induced by intracerebroventricular injection of NT, and capable of concentration- and volume-dependent blockade of NMDA-induced dopamine release.

IDH2R140Q-IN-1 is a potent inhibitor of IDH2R140Q (IC50: 6.1 nM) and can be used in studies of acute myeloid leukemia.

R140309 is an UCHL3 inhibitor.

R1487 Hydrochloride is an orally available, selective and potent inhibitor of mitogen-activated protein kinase (p38α) for the study of metabolic diseases.

R1487 is an orally bioavailable and highly selective p38α mitogen-activated protein kinase inhibitor.

UniPR1449 is an EphA2 receptor antagonist with a KD of 3.8±2.4 μM, which is significant in cancer pathophysiology [1].

UniPR1447 is a dual antagonist for both EphA2 and EphB2 receptors, exhibiting an IC50 value of 6.6 μM against EphA2-ephrin-A1 binding [1].

Compound 28.1, also known as TAS2R14 agonist-2, is a potent and selective inhibitor of TAS2R14, exhibiting an EC50 of 72 nM [1].

TAS2R14 agonist is a potent partial agonist of TAS2R14, displaying an EC50 value of 116.6 ± 23.6 nM [1].

UniPR1454 targets the EphA2 receptor and inhibits the interaction between EphA2 and ephrin A1, with an IC50 of 2.6 μM. Furthermore, UniPR1454 suppresses the proliferation of glioblastoma U251 cells.

JR14a (5-(Bis(4-chlorophenyl)methyl)-3-methylthiophene-2-carbonyl)-l-arginine hydrochloride) is a potent antagonist of human complement C3a receptor.

[SER140]-PLP(139-151) is a polypeptide fragment derived from the myelin-associated lipid protein.

[SER140]-PLP(139-151) acetate is a peptide fragment from myelin proteolipid protein (PLP).

[SER140]-PLP(139-151) (TFA) is a polypeptide fragment of the myelin lipid protein.

[D-Ser14]-Humanin is a biologically active peptide in which the Ser14 residue of Humanin is replaced with its D-form. This variant exhibits effective inhibitory activity against the fibrillation of amyloid-β. Compared to its L-form counterpart, [D-Ser14]-Humanin offers enhanced cellular protective activity against age-related cell death induced by amyloid precursor fibrils and oxidative stress. This compound is utilized in research on Alzheimers disease.

PYR14-TFSI is a room temperature ionic liquid (RTIL) characterized by a wide electrochemical window (5.5V) and high viscosity, making it a promising candidate for electrochemical energy applications.

Amchem R 14 is a biochemical.